MIRA PHARMACEUTICALS, INC. COMMON STOCK (NASDAQ: MIRA)

MIRA PHARMACEUTICALS, INC. COMMON STOCK

NASDAQ: MIRA (MIRA Pharmaceuticals, Inc.)

Kemas kini terakhir: 24 Aug, 11:58PM

1.43

0.03 (2.14%)

Tambah ke senarai pantauan

Penutupan Terdahulu	1.40
Buka	1.40
Jumlah Dagangan	171,063
Purata Dagangan (3B)	1,330,335
Modal Pasaran	27,269,098

Harga / Buku (P/B)

8.10

Julat 52 Minggu

0.730 (-48%) — 2.70 (88%)

Arah Aliran Pasaran

		Jangka Pendek	Jangka Sederhana
Industri	Drug Manufacturers - General (US)	Menaik	Menurun
	Drug Manufacturers - General (Global)	Menaik	Menurun
Stok	MIRA Pharmaceuticals, Inc.	Bercampur	Bercampur

AISkor Stockmoo

-0.5

Konsensus Penganalisis	2.0
Aktiviti Orang Dalam	NA
Volatiliti Harga	-2.0
Purata Bergerak Teknikal	0.0
Osilator Teknikal	-2.0
Purata	-0.50

Saham Serupa

Stok	Modal Pasaran	DY	P/E (TTM)	P/B
MIRA	27 M	-	-	8.10
AMRN	319 M	-	-	0.740
SCLXW	-	-	-	-
AZN	282 B	1.72%	30.18	6.09
SNY	121 B	4.47%	16.24	1.41
AMGN	182 B	2.82%	26.13	19.34

Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
Sektor	Healthcare
Industri	Drug Manufacturers - General
% Dimiliki oleh Orang Dalam	19.68%
% Dimiliki oleh Institusi	5.60%

Pemilikan

Nama	Tarikh	Syer Dipegang
First American Bank	30 Jun 2025	20,000
Cary Street Partners Financial Llc	30 Jun 2025	10,000

Tiada data dalam julat masa ini.

Tarikh	Jenis	Butiran
24 Oct 2025	Pengumuman	MIRA Pharmaceuticals Initiates Multiple Ascending Dose (MAD) Phase 1 Study of Oral Ketamir-2 and Selects Chemotherapy-Induced Neuropathic Pain as Lead Phase 2a Indication
16 Oct 2025	Pengumuman	MIRA Pharmaceuticals Announces Oral Mira-55 Outperformed Injected Morphine in Normalizing Pain and Reducing Inflammation, Supporting Its Planned IND for Chronic Inflammatory Pain
30 Sep 2025	Pengumuman	MIRA Pharmaceuticals Closes Acquisition of SKNY Pharmaceuticals, Expands Pipeline with SKNY-1 for Obesity and Nicotine Addiction
22 Sep 2025	Pengumuman	MIRA Pharmaceuticals Announces Favorable Topline Results from Phase 1 SAD Study of Oral Ketamir-2, a Next-Generation Non-Scheduled Ketamine Analog
16 Sep 2025	Pengumuman	MIRA Pharmaceuticals Reports Positive PTSD Data Demonstrating Ketamir-2 Restores Normalized Behavior in Stressed Animals
12 Sep 2025	Pengumuman	MIRA Pharmaceuticals Shareholders Approve Acquisition of SKNY Pharmaceuticals, Advancing Next-Generation Oral Therapeutic for Obesity and Smoking Cessation

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

Log masuk untuk menambahkan ke senarai pantauan

AI Templat

Peringatan harga anda

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Log masuk untuk menambahkan ke senarai pantauan

Keuntungan Nyata	-
Keuntungan Tidak Nyata	-
Dividen Diterima 2025	-
Jumlah Untung	-
Pulangan Purata	-
Kuantiti (Beli)	-
Purata Harga (Beli)	-
Kuantiti (Jual)	-
Purata Harga (Jual)	-

Log masuk untuk menambahkan ke senarai pantauan

Tiada saham yang memenuhi kriteria anda

Jumlah Hutang/Ekuiti (D/E MRQ)	0.04%
Nisbah Semasa (MRQ)	12.85
Aliran Tunai Operasi (OCF TTM)	-6.14 M
Aliran Tunai Bebas Leveraj (LFCF TTM)	-3.26 M

Pulangan Atas Aset (ROA TTM)	-193.30%
Pulangan Atas Ekuiti (ROE TTM)	-355.82%

Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)